Skip to main content
. 2024 May 29;84(5):443–458. doi: 10.1055/a-2286-6066

Fig. 6.

Fig. 6

 Progression-free survival in the BioItaLEE trial depending on the changes in serum thymidine kinase activity under therapy with ribociclib 15 . HR = hazard ratio, mPFS = median progression-free survival, sTKa = serum thymidine kinase activity

HHS Vulnerability Disclosure